SCHEMBL4618653

SCHEMBL4618653

Cc1ccc(S(=O)(=O)c2ccccc2)c(C)c1S(=O)(=O)NC1CCOCC1

nearest known ligand 0.42

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
ALDH1A1 P00352 6/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
LMNA P02545 2/20 0.39
BRD4 O60885 3/20 0.38
BRD2 P25440 2/20 0.37
BRD3 Q15059 2/20 0.37
WNT3 P56703 2/20 0.36
SFRP1 Q8N474 2/20 0.36
HTR1A P08908 1/20 0.36
HTR7 P34969 1/20 0.36
MAPT P10636 1/20 0.36
MCOLN3 Q8TDD5 1/20 0.36
CCR8 P51685 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6101893 0.81 HTT (0.44) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL6103185 0.80 ALDH1A1 (0.58) ALDH1A1L3MBTL1SMN1; SMN2LMNABRD4
SCHEMBL6101888 0.79 SFRP1 (0.46) MEN1KMT2AALDH1A1L3MBTL1SMN1; SMN2
SCHEMBL18343804 0.76 KDM4E (0.56) ALDH1A1SMN1; SMN2HTR1AHTR7MAPT
SCHEMBL16852665 0.75 GAA (0.52) ALDH1A1LMNABRD4MAPTMCOLN3
SCHEMBL13162704 0.74 PKM (0.51) MEN1KMT2AALDH1A1L3MBTL1LMNA
SCHEMBL6101380 0.73 HTR1A (0.41) ALDH1A1BRD4WNT3SFRP1HTR1A
SCHEMBL4619410 0.72 SFRP1 (0.57) ALDH1A1L3MBTL1SMN1; SMN2BRD4BRD2
SCHEMBL6101508 0.71 SFRP1 (0.52) ALDH1A1L3MBTL1SMN1; SMN2WNT3SFRP1
SCHEMBL6103392 0.70 SFRP1 (0.52) ALDH1A1L3MBTL1SMN1; SMN2WNT3SFRP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP claimed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US claimed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO claimed
EP-1879859-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF Wyeth a Corporation of the State of Delaware (US) 2008-01-23 EP disclosed
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof WYETH (US) 2006-12-07 US disclosed
WO-2006124875-A2 DIARYLSULFONE SULFONAMIDES AND USE THEROF WYETH (US) 2006-11-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060276464-A1 Diarylsulfone sulfonamides and use thereof SFRP1, SOS1, FZD7 MEN1 886/4885KMT2A 3832/4885ALDH1A1 1865/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.